0000899243-21-012915.txt : 20210322 0000899243-21-012915.hdr.sgml : 20210322 20210322191314 ACCESSION NUMBER: 0000899243-21-012915 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210319 FILED AS OF DATE: 20210322 DATE AS OF CHANGE: 20210322 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Giaccia Amato CENTRAL INDEX KEY: 0001753058 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36361 FILM NUMBER: 21762599 MAIL ADDRESS: STREET 1: C/O VERSARTIS, INC. STREET 2: 1020 MARSH ROAD CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aravive, Inc. CENTRAL INDEX KEY: 0001513818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264106690 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: RIVER OAKS TOWER STREET 2: 3730 KIRBY DRIVE, SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: 936-355-1910 MAIL ADDRESS: STREET 1: RIVER OAKS TOWER STREET 2: 3730 KIRBY DRIVE, SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Versartis, Inc. DATE OF NAME CHANGE: 20110223 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-19 0 0001513818 Aravive, Inc. ARAV 0001753058 Giaccia Amato C/O ARAVIVE, INC. 3730 KIRBY DRIVE, SUITE 1200 HOUSTON TX 77098 1 0 0 0 Common Stock 2021-03-19 4 M 0 8055 0.06 A 949935 D Common Stock 2021-03-19 4 M 0 4028 0.06 A 953963 D Common Stock 2021-03-19 5 G 0 E 12083 0.00 D 941880 D Stock Option (Right to buy) 0.06 2021-03-19 4 M 0 8055 0.00 D 2018-10-12 2021-04-25 Common Stock 8055 0 D Stock Option (Right to buy) 0.06 2021-03-19 4 M 0 4028 0.00 D 2018-10-12 2021-04-25 Common Stock 4028 0 D This transaction involved a gift of securities by the reporting person to The Denise Chan Cancer Biology Program Endowed Fund in the Stanford Cancer Institute in the School of Medicine. On April 26, 2011, the reporting person was granted certain options to purchase shares of common stock at an exercise price of $0.02 per share. Pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018 (the "Merger Agreement"), these options were converted into options to purchase an aggregate of 12,083 (8,055 and 4,028) shares of common stock (as adjusted a stock split) of Aravive, Inc. at a per share exercise price of $0.06 per share (as adjusted for a stock split). The options were fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger described in the Merger Agreement. /s/ Abel Svitavsky, Attorney-In-Fact 2021-03-22